Journal profile · Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Cancer Innovation
ISSN 2770-9191 · eISSN 2770-9183 · Wiley · United Kingdom
Cancer Innovation: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 4.1 (journal website); fully open access; APC about USD 2,700; median 120 days to acceptance (70 articles, last 24 months); acceptance rate 20% (journal website); 59 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Cancer Innovation is published by Wiley and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Breast Cancer Treatment Studies and Ferroptosis and cancer prognosis, together about 20.9% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Your research will be free to access, making it available to read, download and share with ease. Quality and impactful research governed by an international and distinguished editorial board. Publish open access at no cost to you - fees are waived from 2022-2024. An official journal of the Boao Cancer Innovation Institute, devoted to innovative and significant research in basic research and clinical oncology, and published on behalf of Tsinghua University Press. Save time formatting your manuscript with free formatting submission. Read the aims and scope
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Editor-in-chief Jian DingPublisher website
Editorial board by country: 48 in mainland China (about 52%); most named Mainland China 48, United States 30, Hong Kong, China 3, United Kingdom 2, Australia 2 (93 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine7.7%
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology7.1%
- Ferroptosis and cancer prognosisMedicine6.1%
- HER2/EGFR in Cancer ResearchMedicine5.5%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance5.1%
- Human auditory perception and evaluationEngineering5.1%
- Educational Robotics and EngineeringComputer Science5.1%
- Lung Cancer Research StudiesMedicine4.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePMCPubMedCASPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 4.1Publisher website ·
- Impact factor (publisher) 2025
- 4.1Publisher website ·
- CiteScore 2026-06
- 4.4LetPub ·
- CiteScore (publisher)
- 4.4Publisher website ·
- CiteScore (publisher) 2025
- 4.4Publisher website ·
- SJR 2026-06
- 0.92LetPub ·
- SNIP 2026-06
- 0.76LetPub ·
- h-index
- 19OpenAlex ·
- i10-index
- 42OpenAlex ·
- 2-year mean citedness
- 3.76OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 43LetPub ·
- Articles per year (publisher)
- 2Publisher website ·
- Articles per year (publisher) 2025
- 49Publisher website ·
- Downloads per year (publisher) 2025
- 103,649Publisher website ·
Articles by year OpenAlex count · 269 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 44 | 44 | 18 |
| 2025 | 59 | 59 | 201 |
| 2024 | 61 | 61 | 398 |
| 2023 | 68 | 68 | 652 |
| 2022 | 37 | 37 | 258 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
120 daysMedian, submission to acceptance · P25–P75 80 days – 184 days
- Acceptance to online
- median 54 days (70 articles)
- Submission to online
- median 189 days
- Sample
- 70 articles with submission and acceptance dates (110 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 12 weeksLetPub ·
- Acceptance rate (publisher)
- 20%Publisher website ·
- Acceptance rate (publisher) 2025
- 20%Publisher website ·
- Submission to first decision
- 7 daysPublisher website ·
- Submission to first decision 2025
- 7 daysPublisher website ·
- Submission to acceptance 2025
- 120 daysPublisher website ·
- Acceptance to publication 2025
- 69 daysPublisher website ·
- Submission to publication (journal-reported)
- about 12 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,700 / GBP 2,250 / EUR 2,590 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,700 / EUR 2,590 / GBP 2,250 | — | — | |
| LetPub | USD 2,800 / GBP 2,060 / EUR 2,428 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted6, with length limits
- case reportThe table below outlines general specifications of the different Canner Innovation article types. Article Type Description Word Limit Abstract / Structure Other…Length not stated
- commentaryThe table below outlines general specifications of the different Canner Innovation article types. Article Type Description Word Limit Abstract / Structure Other…main text ≤ 1,500 words
- original articleThe table below outlines general specifications of the different Canner Innovation article types. Article Type Description Word Limit Abstract / Structure Other…Length not stated
- reviewThe table below outlines general specifications of the different Canner Innovation article types. Article Type Description Word Limit Abstract / Structure Other…Length not stated
- systematic reviewThe table below outlines general specifications of the different Canner Innovation article types. Article Type Description Word Limit Abstract / Structure Other…Length not stated
- technical reportTechnical Report Extensions or updates to previously published research, reporting additional controls; projects that did not yield publishable results but repr…Length not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, License & copyright, Open access, Peer review, Preprints
- Authorship Authorship
All listed authors should have contributed to the manuscript substantially and have agreed to the final submitted version. Review editorial standards and scroll down for a description of authorship criteria.
Source ↗Publisher website ·- Data availability Data Sharing and Data Availability
This journal expects data sharing. Review Wiley's Data Sharing policy where you will be able to see and select the data availability statement that is right for your submission.
Source ↗Publisher website ·- License & copyright Reproduction of Copyright Material
Open access under CC-BY/CC-BY-NC/CC-BY-NC-ND Creative Commons licenses. Model summary
If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is your responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley's Copyright Terms & Conditions FAQ.Authors wishing to include figures, tables, or text passages that have already been published elsewhere (including…
Source ↗Publisher website ·- Open access Open Access
This journal is a gold open access title which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI de…
Source ↗Publisher website ·- Peer review Peer Review
Single-anonymized peer review; at least two anonymous reviewers; papers sent to review only if Editor-in-Chief determines quality and relevance requirements met. Model summary
This journal operates under a single-anonymized peer review model. Except where otherwise stated, manuscripts are peer reviewed by at least two anonymous reviewers. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements. In-house submissions, i.e. papers authored by Editors or Editorial Board members of the title…
Source ↗Publisher website ·- Preprints Preprint Policy
Preprint policy: preprint servers accepted; update pre-publication versions with link to final published article; may post final published version immediately after publication. Model summary
Please find our preprint policy here.This journal accepts articles previously published on preprint servers. You are requested to update any pre-publication versions with a link to the final published article. You may also post the final published version of the article immediately after publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Wiley
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2770-9191
- Electronic ISSN
- 2770-9183
- Society / sponsor
- Boao Cancer Innovation Institute
- Latest issue on the website
- Volume 5, Issue 4 (August 2026)
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Cancer Innovation
What CAS zone is Cancer Innovation in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Innovation is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Innovation?
The journal's website gives an impact factor of 4.1 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 4.4, h-index 19.
How long does peer review take at Cancer Innovation?
Based on the dates recorded on 70 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 120 days (interquartile range 80–184 days); authors report an average review time of about 12 weeks; the journal's website gives an acceptance rate of 20% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Cancer Innovation based?
Of the 93 board members whose country the journal's board page names, 48 (about 52%) are in mainland China; the countries named most often are Mainland China (48), United States (30) and Hong Kong, China (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Innovation?
According to LetPub and DOAJ records, Cancer Innovation is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Web of Science, PMC, PubMed and CAS; that list has not been checked against each database.
Is Cancer Innovation open access, and what is the APC?
Cancer Innovation is a fully open-access journal. APC about USD 2,700.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .